I am an Assistant Professor in Molecular and Genetic Cancer Epidemiology at the Department of Biosciences and Nutrition.
My main scientific interest is in the search of understanding the specific patient and tumor characteristics required throughout tumor progression to enable the cancer tumor to gain early or late metastatic capacity, in the end responsible for virtually all cancer-related death.
I focus my research around breast cancer that is the most common female cancer in the Western world. One in four women diagnosed with breast cancer will later develop distant metastatic disease and die. Breast cancer is widely recognized as a heterogeneous disease in the sense of both primary tumor metastatic capacity as well as time to metastatic spread of disease.
- MSc (Master of Science) in Molecular Biotechnology, Uppsala University.
- PhD in Cancer Epidemiology, Department of Medical Epidemiology and Biostatistics, Karolinska Institutet.
Main research questions:
- Does intra-tumor heterogeneity influence cancer patient survival and response to therapy?
- Breast cancer in situ: Who is at high risk to develop invasive breast cancer?
- Molecular definition of an “indolent” tumor? Identify patients at very low risk for fatal breast cancer.
- Why do young women with breast cancer have poor prognosis?
- Is breast cancer survival inherited?
Academic honours, awards and prizes
- 3-year full Postdoctoral Research position from the Swedish Research Council (Vetenskapsrådet).
- 4-year Young Investigator “Unga Forskare” Project Research Grant from the Swedish Research Council (Vetenskapsrådet).
- 4-year Young Investigator Award from the Swedish Research Council for Health, Working life and Welfare (FORTE).
Breast cancer genetic risk profile is differentially associated with interval and screen-detected breast cancers
Annals of oncology : official journal of the European Society for Medical Oncology 2015;26(3):517-22
Endothelial ALK1 Is a Therapeutic Target to Block Metastatic Dissemination of Breast Cancer
Cancer research 2015;75(12):2445-56
Gene expression profiling of sequential metastatic biopsies for biomarker discovery in breast cancer
Molecular oncology 2015;9(7):1384-91
Immunohistochemistry-based subtypes and gene expression signatures as predictors of prognosis in metastatic breast cancer
JOURNAL OF CLINICAL ONCOLOGY 2015;33(15):-
Intra-tumor heterogeneity of the estrogen receptor predicts less benefit from tamoxifen therapy and poor long-term breast cancer patient survival - Retrospective analyses of the STO3 randomized trial
EUROPEAN JOURNAL OF CANCER 2015;:S269-S269
MammaPrint accurately predicts long-term survival (25 years) and adjuvant tamoxifen therapy benefit in lymph node negative patients
CANCER RESEARCH 2015;:-
Molecular subtype and tumor characteristics of breast cancer metastases as assessed by gene expression significantly influence patient post-relapse survival
Annals of oncology : official journal of the European Society for Medical Oncology 2015;26(1):81-8
2q36.3 is associated with prognosis for oestrogen receptor-negative breast cancer patients treated with chemotherapy
Nature communications 2014;5():4051-
Multi-level gene expression signatures, but not binary, outperform Ki67 for the long term prognostication of breast cancer patients
Molecular oncology 2014;8(3):741-52
Multi-level gene expression signatures, but not binary, outperform Ki67 for the long term prognostication of breast cancer patients (vol 8, pg 741, 2014)
MOLECULAR ONCOLOGY 2014;8(6):1159-1159
Prognostic information of a previously diagnosed sister is an independent prognosticator for a newly diagnosed sister with breast cancer
Annals of oncology : official journal of the European Society for Medical Oncology 2014;25(10):1966-72
Sequential metastatic biopsies and functional imaging in breast cancer
JOURNAL OF CLINICAL ONCOLOGY 2014;32(15):-
Gene signature model predicts metastatic onset better than standard clinical markers - Nested case-control design uniquely enables enrichment for biologically relevant features
CANCER RESEARCH 2013;:-
Clinically Used Breast Cancer Markers Such As Estrogen Receptor, Progesterone Receptor, and Human Epidermal Growth Factor Receptor 2 Are Unstable Throughout Tumor Progression
JOURNAL OF CLINICAL ONCOLOGY 2012;30(21):2601-8
The dyslexia candidate gene DYX1C1 is a potential marker of poor survival in breast cancer
BMC cancer 2012;12():79-
When to order a biopsy to characterise a metastatic relapse in breast cancer
ANNALS OF ONCOLOGY 2012;:x349-53
HER2 status in a population-derived breast cancer cohort: discordances during tumor progression
BREAST CANCER RESEARCH AND TREATMENT 2011;125(2):553-61
Inactivation of FBXW7/hCDC4-beta expression by promoter hypermethylation is associated with favorable prognosis in primary breast cancer
BREAST CANCER RESEARCH 2010;12(6):R105-
Is Genetic Background Important in Lung Cancer Survival?
PLOS ONE 2009;4(5):e5588-
Breast cancer onset in twins and women with bilateral disease
JOURNAL OF CLINICAL ONCOLOGY 2008;26(25):4086-91
Etiology of familial aggregation in melanoma and squamous cell carcinoma of the skin
CANCER EPIDEMIOLOGY BIOMARKERS & PREVENTION 2007;16(8):1639-43
Familial concordance in cancer survival: a Swedish population-based study
LANCET ONCOLOGY 2007;8(11):1001-6
Estimation of genetic and environmental factors for melanoma onset using population-based family data
STATISTICS IN MEDICINE 2006;25(18):3110-23
Is breast cancer prognosis inherited?
BREAST CANCER RESEARCH AND TREATMENT 2006;:S185-S185
Telephone +46-08-524 88117